Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
You may also be interested in...
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
The Amsterdam-based group will use proceeds from the financing to progress its pipeline of genetic modifiers in cancer and rare diseases.
The biotech has 15 pathogens in its sights and is also launching mRNA Access that will grant researchers the opportunity to use Moderna's technology platform to develop vaccines for emerging or neglected infectious diseases.